Pfizer Global Regulatory Affairs
Pfizer Inc.
400 Arcola Road Collegeville, PA 19426

Global Product Development

03 August 2021

Marion Gruber, Ph.D.
Director
Office of Vaccines Research and Review
Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Avenue
WO71, G112
Silver Spring, MD 20993-0002

Re: BLA 125742

COVID-19 mRNA Vaccine (BNT162/PF-07302048)

Response to FDA's 26 July 2021 IR Comments Regarding Manufacturing and Equipment, Including the Remaining Supporting Documents

Dear Dr. Gruber,

Reference is made to the Biologics License Application (BLA) submitted 18 May 2021 for the COVID-19 mRNA Vaccine (BNT162/PF-07302048) developed by BioNTech and Pfizer under BB-IND 19736 for the prevention of COVID-19 caused by SARS-CoV-2 in individuals ≥16 years of age.

Reference is also made to the submission on 30 July 2021 in response to CBER's 26 July 2021 Information Request regarding manufacturing and equipment to Pfizer, received via email from Laura Gottschalk, PhD (CBER/OVRR). Due to the file size of some of the attachments for Response 10, not all the supporting documents were submitted on 30 July 2021.

Specifically, this response includes the remaining supporting documents in response to CBER's 26 July 2021 Information Request regarding manufacturing and equipment, for response #10. The present submission provides Follow-up Response to 26 July 2021 FDA Query #10 in Module 1.11.1.

Should you have any questions regarding this submission, or require additional information, please contact me via phone at 215-280-5503; via facsimile at 845-474-3500; or via e-mail at elisa.harkinstull@pfizer.com.

Sincerely,

Elisa Harkins
Global Regulatory Lead
Global Regulatory Affairs – Vaccines

CC: Ramachandra S. Naik, Ph.D.
CC: Michael Smith, Ph.D.
CC: Laura Gottschalk, Ph.D.